TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
Biotec Betaglucans AS
Closing information (x1000 SEK)
| Closing information | 2025/01 | 2024/01 | 2023/01 |
| Turnover |
44,709
|
32,073
|
16,854 |
| Financial expenses |
1,323
|
1,764
|
2,238 |
| Earnings before taxes |
7,524
|
3,392
|
2,456 |
| Total assets |
33,281
|
32,992
|
23,535 |
| Current assets |
19,083
|
25,079
|
20,449 |
| Current liabilities |
15,996
|
19,108
|
9,410 |
| Equity capital |
17,285
|
13,884
|
14,126 |
| - share capital |
978
|
993
|
1,041 |
Financial ratios
| Fiscal year | 2025/01 | 2024/01 | 2023/01 |
| Solvency |
51.9%
|
42.1%
|
60.0% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
16.8%
|
10.6%
|
14.6% |
| Return on assets (ROA) |
26.6%
|
15.6%
|
19.9% |
| Current ratio |
119.3%
|
131.2%
|
217.3% |
| Return on equity (ROE) |
43.5%
|
24.4%
|
17.4% |
| Change turnover |
13,125
|
16,001
|
-10,109 |
| Change turnover % |
42%
|
100%
|
-37% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2025/01 | 2024/01 | 2023/01 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.